Patients with chronic knee pain due to primary knee osteoarthritis received platelet-rich plasma therapy. chronic pain, primary knee osteoarthritis, platelet-rich plasma
Conditions
Interventions
Patients in the intervention group will follow these guidelines after the PRP injection to his or her knee:
- Within 24 hours after the injection: Apply a cold compress to the knee area and use the kn
Active Comparator Drug,No Intervention No treatment
NSAIDs post-injection protocol
NsPP,Non NSAIDs post-injection protocol
NNsPP
Sponsors
Navamindradhiraj University
Eligibility
Sex/Gender
All
Age
50 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1.) Age between 50-80 years old. 2.) Diagnosed with primary knee osteoarthritis based on ACR criteria. 3.) Radiographic findings of the symptomatic knee fall within Grade II-IV according to the Kellgren-Lawrence Classification. 4.) Visual Analog Scale (VAS) over the past 4 weeks, is equal to or greater than 3.5 points. 5.) Able to voluntarily provide informed consent to participate in the research study.
Exclusion criteria
Exclusion criteria: 1.) History of allergy to medications used in the research study, including Acetaminophen and nonsteroidal anti-inflammatory drugs (NSAIDs). 2.) History of underlying medical conditions that contraindicate the use of study medications, such as peptic ulcer, cardiovascular disease, chronic kidney disease stage III or higher, or chronic liver disease. 3.) History of underlying conditions or medication use that may cause platelet abnormalities, such as thrombocytopenia or the use of medications like Aspirin or Clopidogrel. 4.) No history of receiving osteoarthritis treatments in the form of glucosamine sulfate or chondroitin within the past three months. 5.) Previous knee surgery on the knee that will receive the injection. 6.) Intra-articular injections into the same knee within the past three months. 7.) Contraindications for knee injections, such as active infection around the knee to be injected.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pain score 2, 4, 12, 24, 48 week post-injection Visual-analouge score (VAS) | — |
Secondary
| Measure | Time frame |
|---|---|
| WOMAC Pain 2, 4, 12, 24, 48 week post-injection WOMAC Pain domain,WOMAC Stiffness 2, 4, 12, 24, 48 week post-injection WOMAC Stiffness domain,WOMAC Function 2, 4, 12, 24, 48 week post-injection WOMAC Function domain,Adverse events 2 weeks post-injection Adverse events | — |
Countries
Thailand
Contacts
Public ContactPichayut Wattanapreechanon
Faculty of Medicine Vajira Hospital, Navamindradhiraj University
Outcome results
None listed